Previous studies have implied that targeting RTKs along with their downstream signaling pathways can enhance inhibitory effects, so we seek to further target Axl and MerTK in the setting of HNSCC [80,81,82]. This evidence concerns the gene MERTK and head and neck squamous cell carcinoma.